The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1

Wilmott, James S.; Rizos, Helen; Scolyer, Richard A.; Long, Georgina V.

doi:10.1158/1078-0432.CCR-17-0669

Article navigation

CCR Translations| June 14 2017

The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1

James S. Wilmott;

James S. Wilmott

1Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Helen Rizos;

Helen Rizos

1Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.

2Faculty of Medicine and Health Sciences, Department of Biomedical Sciences, Macquarie University, New South Wales, Australia.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Richard A. Scolyer;

Richard A. Scolyer

1Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.

3Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Georgina V. Long

Georgina V. Long *

1Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.

4Royal North Shore and Mater Hospitals, New South Wales, Australia.

*Corresponding Author: Georgina V. Long, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales 2060, Australia. Phone: 612-9911-7336; Fax: 612-9954-9290; E-mail: [email protected]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: Georgina V. Long, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales 2060, Australia. Phone: 612-9911-7336; Fax: 612-9954-9290; E-mail: [email protected]

Received: April 05 2017

Accepted: April 25 2017

Online ISSN: 1557-3265

Print ISSN: 1078-0432

2017

American Association for Cancer Research.

Clin Cancer Res (2017) 23 (12): 2921–2923.

https://doi.org/10.1158/1078-0432.CCR-17-0669

Abstract

Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them. Clin Cancer Res; 23(12); 2921–3. ©2017 AACR.

See related article by Ascierto et al., p. 3168

2017

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1

Abstract

Citing articles via

Email alerts

AACR Journals

The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1 Available to Purchase

Abstract

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1